Pathological glial reactions in neurodegenerative disorders: prospects for future therapeutics

References

• Reed JC. Apoptosis-based therapies. Nat. Rev. Drug Disc. 11,111–121 (2002).
   Google Scholar
• Mattson MR Apoptosis in neurodegenerative disorders. Nat. Rev Mal Cell Biol. 1,120-129 (2000).
   Google Scholar
• Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases: fiction and facts. Brain Pathol 12,385–390 (2002).
   PubMedGoogle Scholar
• Hirsch EC, Hunot S, Faucheux B etal. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disold 14,383–385 (1999).
   Google Scholar
• Giasson BE, Lee VM. Parkin and the molecular pathways of Parkinson's disease. Neuron 31,885–888 (2001).
   PubMed Web of Science ®Google Scholar
• Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAPK in rat cerebellar granule neurons. Neurosci. Lett. 315,61-64 (2001).
   Google Scholar
• Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of evidence. Neumpathol Appl. Neumbial 27, 257–274 (2001).
   Google Scholar
• Antuono P, Beyer J. The bourdon of dementia. A medical and research perspective. Theor. Med. Bioeth. 20,3–13 (1999).
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Hyman BT Alzheimer's disease therapeutics. I Neuropathol Exp. Neural 60,923–928 (2001).
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study. Int. Ceriatr Pwchiatry14,135–146 (1999).
   Google Scholar
• Mattson MP, Duan W, Pedersen WA, Culmsee C. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 6, 69–81 (2001).
   PubMed Web of Science ®Google Scholar
• Breitner JC. Epidemiologic clues to the causes and routes to prevention of Alzheimer's disease. J. Neural 7iansm. Suppl 59,251–254 (2000).
   Google Scholar
• Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986–990 (1998).
   PubMed Web of Science ®Google Scholar
• Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. Microglial activation in early stages of amyloid-0 protein deposition. Acta Neuropathol 94,316–322 (1997).
   Google Scholar
• Schubert P, Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alz. Dis. Ass. Disoirlers 12,21–28 (1998).
   Google Scholar
• Schubert P, Ogata T, Rudolphi K, Marchini C, McRae A, Ferroni S. Support of homeostatic glial cell signalling: a novel therapeutic approach by propentofylline. Ann. NY Acad. Sci. 826,337–347 (1997).
   PubMedGoogle Scholar
• Kittner B, Roessner M, Rother M. Clinical trials in dementia. Ann. NY Acad. Sri. 826, 307–316 (1997).
   PubMed Web of Science ®Google Scholar
• Jantzen PT, Konnor KE, DiCarlo G eta]. Microglial activation and P-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus preseniline-1 transgenic mice. J. Neurosci 22,2246–2254 (2002).
   Google Scholar
• •Good introduction to the problem of reactive glial cell function (good or bad, or both?).
   Google Scholar
• Raivich G, Bohatschek M, Kloss eta]. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Rev 30,77–105 (1999).
   Google Scholar
• •The activation state of reactive microglia, which determines their potentially neurotoxic power, is reflected by the graded expression of different cell-surface markers.
   Google Scholar
• Haydon PG. Glia: listening and talking to the synapse. Nat. Rev Neurosci. 2,185–193 (2001).
   PubMed Web of Science ®Google Scholar
• •Reviews the evolving essential role of astrocytes for physiological brain function and their active participation in synaptic transmission.
   Google Scholar
• Bezzi P, Domercq M, Brambilla L etal CXCR4-activated astrocyte glutamate release via TNF-a: amplification by microglia triggers neurotoxicity. Nat. Neurosci 4,702–710 (2001).
   Google Scholar
• ••Illustration of the dangerous TNF-amediated (and astrocyte-linked) mechanisms, which allow strengthening of synaptic efficacy but may also turn into a damaging pathomechanism.
   Google Scholar
• Aschner M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neumtoxicology19,269–289 (1998).
   PubMed Web of Science ®Google Scholar
• Giullian D. A strategy for identifying immunosuppressive therapies for Alzheimer's disease. Alzheimer disease and Associated Disarlers12\(Suppl. 2), 7–14 (1998).
   Google Scholar
• Vincent VAM, Tilders FJH, van Dam AM. Inhibition of endotoxin-induced oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor p. Gila 19, 190–198 (1997).
   PubMedGoogle Scholar
• Meda L, Baron P, Scarlato G. Glial activation in Alzheimer's disease: the role of A3 and its associated proteins. Neurobial Aging22, 885–893 (2001).
   Google Scholar
• •Evaluation of the escalating activation of microglia and astrocytes by toxic
   Google Scholar
• Schubert P, Morino T, Miyazaki H etal Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. NY Acad. Sci. 903,24–34 (2000).
   PubMed Web of Science ®Google Scholar
• Schubert P, Ogata T, Marchini C, Ferroni S. Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mech. Aging Develop. 123,47–57 (2001).
   PubMed Web of Science ®Google Scholar
• •Evaluation of possible modes of protection by influencing (potentially neurotoldc) reactive glial cell functions at the second messenger level. Here, the action of the cell modulator, adenosine, which influences the generation and interaction of the second messengers calcium and cyclic AMP may be a promising target for pharmacological intervention.
   Google Scholar
• Hewett SJ, Csernansky CA, Choi DW. Selective potentiation of NMDA induced neuronal injury following induction of astrocytic iNOS. Neumn 13,487–494 (1994).
   Google Scholar
• •Pioneering paper that suggests a possible pathogenic role of reactive astrocytes to oxidative neuronal damage.
   Google Scholar
• LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nature Rev Neumsci. 3,862–872 (2002).
   PubMed Web of Science ®Google Scholar
• Haskew RE, Mongin AA, Kimelberg HK. Peroxynitrite enhances astrocytic volume-sensitive excitatory amino acid release via a src tyrosine kinase-dependent mechanism. J. Neurochem. 82,903–912 (2002).
   Google Scholar
• Alcarna KT, van Eldik U. 3-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-13 and tumor necrosis factor-CL dependent and involves a TNF-a receptor-associated factor and NFkB inducing kinase-dependent signaling mechanism. J. Biol. Chem. 275, 7918–7924 (2000).
   Google Scholar
• Ishii K, Muelhauser F, Liebl U, Beyreuther K. Subacute NO generation induced by Alzheimer's 3-amyloid in the living brain: reversed by inhibition of the inducible NO synthase. FASEBJ 14, 1485–1489 (2000).
   PubMed Web of Science ®Google Scholar
• Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid associated proteins ct-l-antichymotrypsin and apolipoprotein-E assembly of 3-protein into filaments. Nature 372, 92–94 (1994).
   Google Scholar
• •Pioneering paper showing that specific proteins, which can be formed by reactive astrocytes, aggravate P-arnyloid toxicity.
   Google Scholar
• Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Ap toxicity: from top to bottom. Nat. Rev Neurosci 2, 595–598 (2001).
   Google Scholar
• •It is interesting that an impairment of synaptic function is proposed as the major pathomechanism responsible for the generation of dementia.
   Google Scholar
• Selbie LA, Hill S. G-protein coupled receptor crosstalk: the fine-tuning of multiple receptor-signalling pathways. 77PS19, 87–93 (1998).
   Google Scholar
• •The evolving sophisticated signaling cross-talk may be a promising target for future therapy.
   Google Scholar
• Ongini E, Schubert P. Neuroprotection induced by stimulating Al or blocking A2a adenosine receptors: an apparent paradox. Drug Devel Res. 45, 387–393 (1998).
   Google Scholar
• Sebastiao A, Ribieiro J. Fine tuning neuromodulation by adenosine. Trends Pharmacol Sri. 21, 341–361 (2000).
   PubMed Web of Science ®Google Scholar
• •Recently reviewed the fine-tuning modulation of various cell functions by adenosine.
   Google Scholar
• Moreau JL, Huber G. Central adenosine A (A2A) receptors: an overview. Brain Res. Rev. 31, 65–82 (1999).
   Google Scholar
• Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 812, 97–104 (1998).
   PubMed Web of Science ®Google Scholar
• Ogata T, Kohgami S, Okumura H eta]. Nitric oxide-induced neurotoxicity is inhibited by propentofylline via cyclic GMP elevation. Neurobiol Aging 19, 255 (1998).
   Google Scholar
• Takuma K, Phuagphong P, Lee E, Mori K, Baba A, Matsuda T Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeability transition pore. J Biol. Chem. 276, 48093–48099 (2001).
   PubMed Web of Science ®Google Scholar
• Lee SF, Chao MV Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. 98, 3555–3560 (2001).
   PubMed Web of Science ®Google Scholar
• ••Very interesting idea of the newly evolvingcapability of adenosine to mediate a cross-talk between different signaling pathways at the second messenger level. Reinforcement of this adenosine action may provide a chance to recover pathologically impaired pathways, such as NGF producing neurotrophic pathways.
   Google Scholar
• Neumann H, Misgeld T, Matsauro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl Acad. Sci. (USA) 95, 5779–5784 (1998).
   Google Scholar
• Ogata T, Nakamura,Y, Schuber Potentiated cAMP rise in metabotropically stimulated rat cultured astrocytes by a Ca2trelated A1/A2 adenosine receptor co-operation. Eur. I Neumsci. 8, 1124–1131 (1996).
   Google Scholar
• •Experimental evaluation of the adenosine mediated interaction between the second messengers calcium and cAMP in cultured astrocytes.
   Google Scholar
• Ferroni S, Marchini C, Ogata T, Schubert P. Recovery of deficient cholinergic calcium signaling by adenosine in cultured rat cortical astrocytes. j Neurosci. Res. 68, 615–621 (2002). A further example of the newly evolving capability of adenosine to mediate a cross-talk between different signaling pathways at the second messenger level. Reinforcement of this adenosine action may provide a chance to recover pathologically impaired pathways, such as the deficient muscarinic signaling in Alzheimer's disease.
   Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann. Rev. Immunol 18, 217–242 (2000).
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das P etal A subset of NSAIDs lower amyloidogenic Abeta42 independent of cyclooxygenase activity. Natum 414, 159–160 (2001).
   PubMedGoogle Scholar
• •An evolving possibility of pharmacological interference with p-arnyloid toxicity.
   Google Scholar
• McGeer P, McGeerEG. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging22, 799–809 (2001).
   PubMed Web of Science ®Google Scholar
• ••Highly authentic view of the presumed significance of reactive microglia for neuronal damage.
   Google Scholar
• Bin L, Jau-Shyong H. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. JPET304, 1–7 (2003).
   PubMedGoogle Scholar
• •Recently reviewed the presumed significance of reactive microglia for neuronal damage.
   Google Scholar